Easy Breathe Develops New Way for Users to Get Their CPAP Prescription Renewed Quickly Online

Easy Breathe, the online CPAP store, was founded with the purpose of making CPAP therapy easier, and the company’s dedication to this mission has propelled them to the top of their industry.  Continuing their pursuit of this goal, Easy Breathe recently introduced their CPAP Rx Renewal program, which allows customers to quickly refill their CPAP prescriptions from the comfort of their own home.

Easy Breathe is one of the only CPAP companies that offers its customers the option to get their prescription renewed online, a benefit that has become even more important for customers during the COVID-19 pandemic.

To get a CPAP Rx renewed online requires only a few simple steps:

  1. Add the CPAP Prescription to your cart and checkout
  2. Fill out the short questionnaire that’s emailed to you
  3. One of Easy Breathe’s board-certified, licensed doctors reviews your questionnaire and writes your prescription
  4. A copy of your prescription will be emailed to you, and will be good for 8 years

“Setting up our CPAP Prescription Renewal program was a no-brainer for Easy Breathe,” said Nick Weiss, CEO and Founder of Easy Breathe. “It’s because of this service that many people are able to get their Rx renewed without an additional sleep test or visit to their doctor, saving them time and money while ensuring they are getting the products and services they need.”

The CPAP Prescription Renewal program is just one of the ways that Easy Breathe has been making CPAP easier for people with sleep apnea.  For people who have not been tested for sleep apnea, Easy Breathe offers their Easy Sleep Apnea Test (ESAT) which allows customers to get tested and receive a prescription for a CPAP without ever leaving their home.

Additionally, Easy Breathe has committed itself to making CPAP more affordable by implementing payment plan options for all of its most popular products including masks, machines, and CPAP cleaners.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”